^
    2d
    BEAVER: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • KIAA1549
    |
    BRAF mutation • BRAF V600K • BRAF fusion
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    5d
    BECOME-MB: Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, UNICANCER | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    5d
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=267, Recruiting, Pfizer | Trial completion date: Aug 2030 --> Oct 2029 | Trial primary completion date: Feb 2029 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    BRAF V600E • MSI-H/dMMR
    |
    Erbitux (cetuximab) • 5-fluorouracil • Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • claturafenib (PF-07799933) • midazolam hydrochloride
    6d
    NCI-2020-07748: Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma (clinicaltrials.gov)
    P2, N=25, Recruiting, University of California, San Francisco | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    imatinib • Mektovi (binimetinib)
    16d
    Repurposing the MEK inhibitor binimetinib as a dual anti-inflammatory and antifibrotic agent in pulmonary fibrosis. (PubMed, J Thorac Dis)
    Furthermore, binimetinib attenuated the overall activation of pulmonary macrophages through inhibition of the JAK/STAT pathway. In summary, binimetinib exerted potent anti-inflammatory and antifibrotic effects by suppressing the activation of both fibroblasts and pulmonary macrophages, ultimately mitigating bleomycin-induced pulmonary fibrosis in mice.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Mektovi (binimetinib)
    22d
    Immune checkpoint inhibitor-associated lymphocytic colitis in a patient with metastatic melanoma. (PubMed, BMJ Case Rep)
    We describe the case of a man in his 60s with metastatic melanoma on encorafenib/binimetinib and nivolumab/relatlimab, with a history of immune checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting and profuse watery diarrhoea. His symptoms persisted despite discontinuation of Braftovi-Mektovi (BRAF-MEK) therapy and required escalation of corticosteroid therapy and budesonide initiation. This case highlights the diagnostic challenges of differentiating ICI-mediated colitis from adverse events of targeted therapy and underscores the importance of endoscopic and histological confirmation in guiding treatment.
    Journal • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • Mektovi (binimetinib) • Braftovi (encorafenib) • relatlimab (BMS-986016)
    23d
    Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer. (PubMed, Invest New Drugs)
    Despite additive anti-tumor activity for FGFR and MEK inhibition in KRASmt NSCLC lines, the trial was stopped after dose escalation, as no RP2D was identified for futibatinib/binimetinib due to reversible retinopathies. Trial register number. NCT04965818. Trial registration date. 20-September-2021.
    Preclinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • FGFR2 (Fibroblast growth factor receptor 2)
    |
    KRAS mutation • FGFR2 fusion
    |
    Mektovi (binimetinib) • Lytgobi (futibatinib)
    1m
    EAY131-Z1A: Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation
    |
    Mektovi (binimetinib)
    1m
    The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials (clinicaltrials.gov)
    P4, N=46, Recruiting, Pfizer | N=71 --> 46
    Enrollment change
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib) • Kisqali (ribociclib)
    1m
    KN-8701: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors (clinicaltrials.gov)
    P1, N=400, Active, not recruiting, Pierre Fabre Medicament | N=182 --> 400
    Enrollment change
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation • NRAS mutation
    |
    Mektovi (binimetinib) • exarafenib (KIN-2787)
    2ms
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=267, Recruiting, Pfizer | Trial completion date: May 2030 --> Aug 2030 | Trial primary completion date: Nov 2028 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    BRAF V600E • MSI-H/dMMR
    |
    Erbitux (cetuximab) • 5-fluorouracil • Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • claturafenib (PF-07799933) • midazolam hydrochloride
    2ms
    SuRage-EB: Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib (clinicaltrials.gov)
    P4, N=0, Withdrawn, SRH Wald-Klinikum Gera GmbH | N=101 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)